文献速递血栓与止血

Ad26.COV2.S疫苗接种后无影像学血栓证据的VITT病例

VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis.
PubMed 文献 · Blood Adv · 2021-01-01

报告一例年轻男性在接种Ad26.COV2.S新冠疫苗13天后诊断为疫苗诱导免疫性血栓性血小板减少症(VITT),表现为左腿疼痛、血小板减少、低纤维蛋白原血症和D-二聚体显著升高,但影像学未见血栓。尽管影像阴性,基于临床高度怀疑启动静脉免疫球蛋白、泼尼松和阿加曲班治疗,7天后好转出院,血小板因子4抗体检测阳性。这是首例Ad26.COV2.S接种后无影像学可证实血栓的VITT报道。

要点

  • 接种腺病毒载体新冠疫苗后出现血小板减少和凝血异常需警惕VITT。
  • 影像学无血栓证据时,若临床高度疑似VITT仍应尽早启动治疗。
  • VITT早期识别和治疗可预防严重血栓并发症。

核心结论

  • Ad26.COV2.S疫苗接种后可发生无影像学可证实血栓的VITT,早期识别和治疗可改善预后。

研究设计与样本

  • 单例病例报告:一名年轻男性接种Ad26.COV2.S疫苗13天后出现症状。

主要发现

  • 患者表现为5天进行性左腿疼痛、血小板减少、低纤维蛋白原血症和D-二聚体显著升高,但影像学未见血栓。
  • 接受静脉免疫球蛋白、泼尼松和阿加曲班治疗后7天好转出院。
  • 血小板因子4酶联免疫吸附试验抗体检测在治疗启动后返回阳性。

临床怎么用

  • 了解患者疫苗接种状态,在临床高度怀疑VITT时即使无影像学血栓证据也应尽早启动治疗。
  • 早期识别和治疗VITT有助于预防严重血栓并发症。

局限性

  • 单例病例报告,结论推广受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report a case of vaccine-induced immune thrombotic thrombocytopenia (VITT) in a young man diagnosed 13 days after Ad26.COV2.S COVID-19 (Johnson & Johnson/Janssen) vaccination. He presented to us with 5 days of progressive left leg pain, thrombocytopenia, hypofibrinogenemia, and markedly elevated d-dimers, but without radiographically demonstrable thrombosis. Despite negative imaging, we initiated treatment of presumptive VITT given the striking clinical picture that included the timing of his recent adenovirus-based COVID-19 vaccine, leg symptoms, marked thrombocytopenia, and consumptive coagulopathy. He received intravenous immune globulin, prednisone, and argatroban and was discharged 7 days later much improved. His positive platelet factor 4 enzyme-linked immunosorbent assay antibody test returned after treatment was initiated. To our knowledge, this is the first reported case of VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis. Our patient highlights the importance of knowing vaccine status and initiating treatment as soon as possible in the right clinical setting, even in the absence of radiographic evidence of thrombus. Early VITT recognition and treatment provide an opportunity to prevent serious thrombotic complications.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kennedy VE, Wong CC, Hong JM, et al. VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis. Blood Adv. 2021. PMID: 34587255. doi:10.1182/bloodadvances.2021005388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。